Looking for breakthrough ideas for innovation challenges? Try Patsnap Eureka!

Pharmaceutical combinations of histone deacetylase inhibitor and proteasome inhibitor or immunomodulatory drug for the treatment of hematological cancer

A technology for proteasome inhibitors and immunomodulatory drugs, which are used in drug combinations, enzyme inhibitor components, active ingredients of boron compounds, etc.

Pending Publication Date: 2019-05-21
CHONG KUN DONG CORP
View PDF7 Cites 2 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

As mentioned above, HDAC inhibitors are known to be effective in inhibiting cancer growth in multiple myeloma, but ...

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Pharmaceutical combinations of histone deacetylase inhibitor and proteasome inhibitor or immunomodulatory drug for the treatment of hematological cancer
  • Pharmaceutical combinations of histone deacetylase inhibitor and proteasome inhibitor or immunomodulatory drug for the treatment of hematological cancer
  • Pharmaceutical combinations of histone deacetylase inhibitor and proteasome inhibitor or immunomodulatory drug for the treatment of hematological cancer

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0046]

[0047] 1-1) Experimental method

[0048] a. Preparation of animal tumor models

[0049] The human multiple myeloma cell line MM.1s was purchased from ATCC (USA). The MM.1s cell line was maintained with RPMI1640 (Gibco, USA) containing 10% fetal bovine serum (FBS; Gibco, Grand Island, NY, USA).

[0050] MM.1s cells mixed with Matrigel were subcutaneously administered to NOD.CB17-Prkdcscid / NCrHsd male mice (2×10 7 cells / head), grouped to make the tumor size evenly distributed, and then used in the experiment.

[0051] b. Preparation of active ingredients

[0052] The compound of Chemical Formula 1 was prepared at a concentration of 4 mg / ml by dissolving with a physiological saline solution.

[0053] Bortezomib was prepared at a concentration of 0.005 mg / ml by dissolving with physiological saline solution.

[0054] Dexamethasone was prepared at a concentration of 0.05 mg / ml by diluting the 5 mg / mL stock solution with physiological saline solution.

[...

Embodiment 2

[0072]

[0073] 2-1) Experimental method

[0074] a. Preparation of animal tumor models

[0075] The human multiple myeloma cell line MM.1s was purchased from ATCC (USA). The MM.1s cell line was maintained with RPMI1640 (Gibco, USA) containing 10% fetal bovine serum (FBS; Gibco, Grand Island, NY, USA).

[0076] MM.1s cells mixed with Matrigel were subcutaneously administered to NOD.CB17-Prkdcscid / NCrHsd male mice (2×10 7 cells / head), grouped to make the tumor size evenly distributed, and then used in the experiment.

[0077] b. Preparation of active ingredients

[0078] The compound of Chemical Formula 1 was prepared at a concentration of 6 mg / ml by dissolving with a physiological saline solution.

[0079] Lenalidomide was prepared at a concentration of 1 mg / ml by dissolving 1% HCl in PBS and then titrating to neutral pH.

[0080] Dexamethasone at a concentration of 0.2 mg / ml was prepared by diluting 5 mg / ml dexamethasone with physiological saline.

[0081] P...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

No PUM Login to View More

Abstract

The present invention relates to a pharmaceutical combination for treating a hematological cancer comprising the histone deacetylase (HDAC) inhibitor of the chemical formula 1, a proteasome inhibitoror an immunomodulatory drug and a steroidal anti-cancer agent together. The pharmaceutical combination of the present invention can be useful for treating a hematological cancer such as multiple myeloma, by reducing toxicity which is the problem of the conventional HDAC inhibitor and exhibiting an equivalent level of pharmaceutical effects due to a complex inhibitory mechanism against the cancer of the compound of chemical formula 1 and its pharmaceutically acceptable salt, the proteasome inhibitor or the immunomodulatory drug and the steroidal anti-cancer agent.

Description

technical field [0001] The present invention relates to a pharmaceutical composition for treating blood cancer, more particularly to a pharmaceutical composition for treating multiple myeloma, especially to a medicine for treating blood cancer resistant to conventional therapy A pharmaceutical composition, and more particularly to a pharmaceutical composition comprising a histone deacetylase (HDAC), a proteasome inhibitor or an immunomodulatory drug and a steroidal anticancer agent for treating hematological cancer. Background technique [0002] Myeloma, a blood cancer, refers to tumors made up of the type of cells normally found in the bone marrow. In addition, multiple myeloma (MM) refers to a disseminated malignancy of plasma cells characterized by multiple myeloid neoplastic lesions and secretion of M components (monoclonal immunoglobulin fragments), which are associated with bone pain, pathological fractures, and , hypercalcemia, and normocytic normochromic anemia asso...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
no application Login to View More
IPC IPC(8): A61K31/496A61K31/416A61K31/69A61K31/56A61K31/573
CPCA61K31/454A61K31/496A61K31/573A61K31/69A61K38/005A61P35/00A61K2300/00A61K31/416A61K31/56A61K45/06A61K38/05A61P35/02
Inventor 金秀珍
Owner CHONG KUN DONG CORP
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Patsnap Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Patsnap Eureka Blog
Learn More
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic, Popular Technical Reports.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap|About US| Contact US: help@patsnap.com